Alzheimer's Disease Calcium Homeostasis and Channel Modulator Companies
Overview
Mermaid diagram (expand to render)
This category covers companies developing next-generation calcium homeostasis modulators for Alzheimer's disease beyond conventional L-type, T-type, and N-type calcium channel blockers. The calcium hypothesis of AD, first proposed by Khachaturian in 1989[@khachaturian1989], posits that dysregulated intracellular calcium signaling is a central driver of neurodegeneration. While traditional calcium channel modulators target surface membrane channels, this field focuses on:
Calcium-sensing receptor (CaSR) agonists and positive allosteric modulators
These targets address calcium dysregulation at the subcellular level, including endoplasmic reticulum calcium stores, mitochondrial calcium uptake, and nuclear calcium signaling.
Scientific Rationale
Calcium-Sensing Receptor (CaSR)
The CaSR is a G protein-coupled receptor (GPCR) that monitors extracellular calcium levels and regulates cellular calcium homeostasis. In the brain, CaSR is expressed in neurons and glia, playing roles in:
Synaptic plasticity: CaSR activation modulates NMDA receptor function and long-term potentiation
Neuroprotection: CaSR agonists can reduce excitotoxicity and amyloid-beta toxicity
Targeting CaSR offers a mechanism distinct from voltage-gated calcium channels, with potential for allosteric modulation to achieve selectivity.
Store-Operated Calcium Entry (SOCE)
SOCE is the major pathway for calcium influx in non-excitable cells and operates in neurons through the STIM1 (stromal interaction molecule 1) and ORAI1 (orai calcium release-activated calcium modulator 1) proteins. Key features:
ER calcium depletion triggers STIM1 oligomerization and ORAI1 activation
Excessive SOCE is implicated in amyloid-beta-induced neuronal death
STIM1/ORAI1 axis is upregulated in AD brains, contributing to calcium overload[@soc_brain_path]
SOCE inhibitors offer a targeted approach to normalize calcium influx without broadly suppressing neuronal activity.
Mitochondrial Calcium Uniporter (MCU)
The MCU complex is the primary pathway for mitochondrial calcium uptake. In AD:
Calcium overload in mitochondria triggers permeability transition and cell death
MCU dysfunction contributes to bioenergetic failure in neurons
Selectivity is critical — global calcium blockade is toxic, but mitochondrial-specific targeting preserves normal neuronal function[@soc_mcdonnell2024]
Calmodulin
Calmodulin is a calcium-binding messenger that transduces calcium signals into cellular responses. In AD:
Calmodulin-dependent kinases phosphorylate tau at AD-relevant sites
Calmodulin inhibitors may reduce tau pathology and improve synaptic function[@calmodulin_ad]
Parvalbumin and Calbindin
These calcium-buffering proteins regulate intracellular calcium dynamics. Loss of parvalbumin-positive interneurons is observed in AD, contributing to network hyperexcitability.
Key Companies and Programs
Calcium-Sensing Receptor (CaSR) Modulators
CalciMedica
Headquarters: La Jolla, California, USA
Founded: 2007
Focus: CaSR antagonists for critical care and inflammatory diseases, with emerging CNS applications
Technology: Structure-based design targeting CaMKII and CaMKIV, which are overactivated by amyloid-beta and promote tau phosphorylation[@calmodulin_ad]
Relevance: CaMKII inhibition reduces tau hyperphosphorylation while preserving synaptic plasticity
Relevance: PDE1 is activated by calcium/calmodulin; inhibition may improve synaptic function and memory in AD
Calcium Buffering Protein Modulators
SynapseDx
Focus: Parvalbumin replacement and enhancement strategies
Technology: Peptide mimetics of parvalbumin calcium-binding domains
Stage: Discovery
Relevance: Restoring parvalbumin in fast-spiking interneurons may normalize inhibitory tone and reduce network hyperexcitability in AD
L-Type and N-Type Calcium Channel Modulators (Specialized AD Focus)
Vanderbilt University / NIH Blueprint Program
Institution: Vanderbilt University Medical Center
Focus: Development of selective N-type (Cav2.2) calcium channel blockers with enhanced brain penetration for AD
Technology: Peptide toxins and small molecules targeting Cav2.2 over Cav1.x channels
Stage: Preclinical
Relevance: N-type channel blockade reduces excitatory neurotransmitter release and protects against excitotoxicity
Merck & Co.
Program: Previous research on L-type calcium channel blockers (nimodipine, isradipine) for AD showed limited efficacy
Current Focus: Repositioning to Cav1.3-selective modulators (to avoid cardiovascular effects of broad L-type blockade) and R-type (Cav2.3) calcium channels
Technology: Subtype-selective compounds with improved selectivity profiles
Stage: Discovery
Note: Earlier clinical trials with non-selective L-type blockers were largely negative, but Cav1.3 selectivity may improve the risk/benefit ratio
See: [Merck](/companies/merck)
Pipeline Summary
| Company | Mechanism | Target | AD Program | Stage | |---------|-----------|--------|------------|-------| | CalciMedica | SOCE inhibitor | STIM1/ORAI1 | CM-02 | Preclinical | | CalciMedica | CaSR modulator | Calcium-sensing receptor | CM series | Discovery | | NodThera | CaSR/NLRP3 | Allosteric modulator | NT series | Discovery | | Accerise | CaMK inhibitor | CaMKII/IV | ACC-CAL | Discovery | | BioKyra | PDE1 inhibitor | Calmodulin pathway | BK series | Lead opt. | | Khlorum | MCU blocker | Mitochondrial Ca2+ uptake | KH series | Discovery | | SynapseDx | PV mimetic | Parvalbumin replacement | SY series | Discovery | | Kal Pharmaceuticals | CaSR PAM | Calcium-sensing receptor | KP-001, KP-002 | Preclinical | | Vanderbilt/NIH | N-type blocker | Cav2.2 | Research program | Preclinical |
Therapeutic Rationale and Clinical Strategy
Why Calcium Homeostasis?
Calcium dysregulation is one of the earliest and most consistent features of AD, preceding amyloid and tau pathology[@laferla2002]. The calcium hypothesis posits that:
Aging causes gradual impairment of calcium regulatory systems
Amyloid-beta amplifies calcium dysregulation through channel formation and receptor modulation
Tau pathology disrupts calcium homeostasis via dendritic spine loss and mitochondrial dysfunction
Excessive intracellular calcium activates destructive enzymatic pathways (calpains, caspases, kinases) and leads to mitochondrial failure
Advantages of Subcellular Targeting
Compared to traditional L-type/T-type channel blockers, subcellular calcium modulators offer:
Selectivity: Target only pathological calcium signals, preserving normal synaptic function
Disease-modifying potential: Address upstream calcium dysregulation rather than downstream symptoms
Combination potential: Complement amyloid/tau-targeting therapies without mechanism conflict